Goldman Sachs lifts target for AbbVie stock to USD 294.00

Published on 10/26/2026 at 16:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AbbVie reports on October 30, 2026. AbbVie stock costs EUR 256.45 on October 26, 2026, plus 0.81 percent versus the October 23, 2026 Xetra close.

Analyst target and reporting date

On October 22, 2026, Goldman Sachs raised its AbbVie target from USD 258.00 to USD 294.00.
AbbVie will report third-quarter 2026 results on October 30, 2026, before markets open.
AbbVie stock costs EUR 256.45 at Lang & Schwarz on October 26, 2026 at 4:37 p.m. CET, plus 0.81 percent versus the Xetra close.

AbbVie Inc., US00287Y1091, Illustration mit AI erstellt.

Goldman Sachs raised its AbbVie target from USD 258.00 to USD 294.00 on October 22, 2026, while keeping a Neutral rating, according to Markets Insider. The target is 2.49 percent above AbbVie's USD 286.85 primary-market price at 11:44 a.m. EDT on October 26, 2026. At Lang & Schwarz, the stock was trading at EUR 256.45 on October 26, 2026 at 4:37 p.m. CET, plus 0.81 percent versus the Xetra close of October 23, 2026 at EUR 254.40.

October 30 sets the next test

AbbVie will release its third-quarter 2026 results before the US market opens on October 30, 2026, and will hold its earnings call at 8:00 a.m. Central time. The date was announced by AbbVie on October 1, 2026, in its AbbVie release.

Growth is visible in margins

In the second quarter of 2026, AbbVie reported an adjusted operating margin of 48.30 percent and adjusted earnings per share of USD 3.65. The figures included a USD 0.17 unfavorable impact from acquired in-process research and development expenses, according to the Yahoo Finance transcript. Skyrizi sales reached USD 5.50 billion in that quarter and grew 24.00 percent on an operational basis.

Stock remains near its yearly high

AbbVie's USD 286.85 primary-market price stood 1.55 percent below its 52-week high of USD 291.40 and 50.19 percent above its 52-week low of USD 190.75 on October 26, 2026. The company had a market capitalization of USD 506.9 billion, a price-to-earnings ratio of 80.78 and a dividend yield of 2.00 percent on the same date.

What does the target imply?

The Goldman Sachs target sits above the current primary-market price, but the firm's Neutral rating keeps the assessment balanced. The next results therefore provide the nearer test for whether AbbVie's commercial performance can support the valuation and the analyst's USD 294.00 objective.

Comparison with peers

AbbVie Inc.: plus 0.81 percent, price-to-earnings ratio 80.78, market capitalization USD 506.9 billion.

Amgen: plus 0.33 percent, price-to-earnings ratio 27.40, market capitalization USD 238.3 billion.

Gilead Sciences: plus 1.61 percent, market capitalization USD 196.6 billion.

Euro quote stays above Xetra

The stock was trading at EUR 256.45 at Lang & Schwarz on October 26, 2026 at 4:37 p.m. CET, up EUR 2.05 or 0.81 percent versus the Xetra close of October 23, 2026 at EUR 254.40. The next scheduled company date is October 30, 2026, when AbbVie reports third-quarter results before the US market opens. The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.